Titlebook: Cellular Primary Immunodeficiencies; Mario Milco D‘Elios,Cosima Tatiana Baldari,Frances Book 2021 Springer Nature Switzerland AG 2021 T Ce

Cholecystokinin

mettlesome

Management of Cellular Immunodeficiencies, cell and/or B cell dysfunction. Hematopoietic stem cell transplantation (HSCT) represents a curative treatment in certain patients with cellular immunodeficiency; enzyme replacement therapy and gene therapy may be further options in very specific settings. Apart from disease-specific treatments, an

商談

Vaccines in Cellular Immunodeficiencies,by vaccines is among the most effective healthcare measures mainly for these subjects. As in humoral immune deficiencies, . specific . be deepened. Firstly, response to vaccine is often seriously compromised in patients affected by cellular immunodeficiencies so that some vaccines result inefficacio

有發(fā)明天才

Gene Therapy in Cellular Immunodeficiencies,loHSCT). However, while this therapy is curative for many PIDs, the procedure requires a suitably matched donor and carries significant risks of morbidity and mortality from complications such as graft-versus-host disease (GVHD). Autologous gene therapy (GT) approaches using stem cells isolated from

Postulate

2282-6505 rheumatologists, oncologists, internists, and infectious disease specialists and will also be informative for MD, Master and PhD students..978-3-030-70109-3978-3-030-70107-9Series ISSN 2282-6505 Series E-ISSN 2283-6403